Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
GLP-1 medications work in part by slowing down digestion and changing how quickly food moves through the stomach
For some people, they may help
[DOI] [PMC free article] [PubMed] [Google Scholar] [25].Bowden J., Del Greco M F., Minelli C., Davey Smith G., Sheehan N., and Thompson J., A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization, Stat Med, vol
I knew the process
meningitidis lysosomal killing in vitro and reduces meningococcal epithelial transmigration rate (Lidberg et al., 2025b)
